- Home
- INKT vs MDCX Comparison
INKT vs MDCX Comparison
Compare INKT & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INKT | MDCX |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.6M | 31.1M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | INKT | MDCX |
|---|---|---|
| Price | $11.27 | $1.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $35.00 | $23.50 |
| AVG Volume (30 Days) | 10.4K | ★ 376.2K |
| Earning Date | 03-17-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.34 | $0.94 |
| 52 Week High | $76.00 | $8.94 |
Technical Indicators
Market Signals| Indicator | INKT | MDCX |
|---|---|---|
| Relative Strength Index (RSI) | 41.88 | 22.64 |
| Support Level | $10.98 | $1.09 |
| Resistance Level | $11.48 | $1.29 |
| Average True Range (ATR) | 0.46 | 0.13 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 17.35 | 9.84 |
Price Performance
Historical ComparisonAbout INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
About MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.